The ‘very, very bad look' of remdesivir, the first FDA-approved COVID-19 drug
Key Excerpts from Article on Website of Science
Posted: October 24th, 2022
October was a good month for Gilead Sciences, the giant manufacturer of antivirals. On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19—a deal potentially worth more than $1 billion. Two weeks later, on 22 October, the U.S. Food and Drug Administration (FDA) approved remdesivir for use against the pandemic coronavirus SARS-CoV-2 in the United States. Both decisions baffled scientists who have closely watched the clinical trials of remdesivir unfold. At best, one large, well-designed study found remdesivir modestly reduced the time to recover from COVID-19 in hospitalized patients with severe illness. A few smaller studies found no impact of treatment on the disease whatsoever. Then ... the World Health Organization's (WHO's) Solidarity trial showed that remdesivir does not reduce mortality or the time COVID-19 patients take to recover. Both [the] FDA's decision and the EU deal came about under unusual circumstances that gave the company important advantages. FDA never consulted a group of outside experts that it has at the ready to weigh in on complicated antiviral drug issues. The European Union, meanwhile, decided to settle on the remdesivir pricing exactly 1 week before the disappointing Solidarity trial results came out. Gilead, having donated remdesivir to the trial, was informed of the data on 23 September and knew the trial was a bust.
Note: Remdesivir had never been approved by the FDA for use before Oct. 2020, yet was rushed through the approval process, while Nobel-prize winning drug Ivermectin was all but banned, even though there was minimal evidence of harm. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.